Iranian Researchers Discover Recombinant Vaccine Formulation for Viral Diseases
Dr. Maria Beihaghi, the managing director of the knowledge-based company, located at Ferdowsi University of Mashahd in the Northeastern part of Iran said in an interview with local media that production of biotechnology products, diagnostic kits, smart polymeric drug delivery systems and biotechnology products are the research field of their company and said.
Regarding the biotechnology products of the knowledge-based company, she said, “This product is a recombinant protein based on cytokine genes attached to the CCR7 receptor. This recombinant protein was registered in the US Patent and Trademark Office.”
According to the researcher, this recombinant protein is considered a type of vaccine for viral diseases, and it has been patented in the United States under the title "Cytokine-based multi-epitope protein for binding to ccr7-positive cells".
She further said that the cytokine-based multi-epitope protein is used both for early diagnosis of cancer and for vaccine production.
“If a patient is in a condition when the doctor cannot diagnose his/her physical condition and underlying diseases, these kits can diagnose their diseases depending on the genes of the patient,” she went on to say.
She described drug dosage calculations as one of the other uses of the kit, saying, “If a drug is prescribed for an individual, this kit based on cytochrome P450 enzyme or CYP (a large group of hemoprotein enzyme), using the varieties of these enzymes it calculates the doses of the drug.”
The researcher further pointed out that in the hospital, if the patient cannot declare his underlying condition, the doctor can diagnose a wide range of diseases by examining his genes with a PCR test; because the cytochrome P450 enzyme is a liver enzyme, and accordingly, we designed a kit that is able to examine genes and diagnose what disease a person has. In the meantime, it also determines the dose of medicine.
The managing director of this knowledge-based company further referred to the production of smart pharmaceutical polymers in their company, saying, “These polymers are a type of targeted drug delivery (TDD) that bring the drug to the target tissue.”
4155/i
